San Francisco, CA, United States of America

Richard T Beresis

This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Icahn School of Medicine at Mount Sinai, The United States Government as Represented by the Department of Veterans Affairs. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard T Beresis. Retrieved from https://idiyas.com/inventor/richard-t-beresis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Richard T. Beresis: Inventor in Biomedical Research

Introduction

Richard T. Beresis is an inventor associated with San Francisco, California. His patent work includes research into compounds that may help address fibrotic diseases, including kidney fibrosis. The available information lists 2 patents.

Latest Patents

One of Beresis’s listed patents is titled “Oxygen-Containing Heterocyclic Compound and Use Thereof.” It describes oxadiazolyl dihydropyrano[2,3-b]pyridine compounds that inhibit HIPK2 and are proposed for treating kidney fibrosis.

The disclosed compounds selectively inhibit Smad3 activation. They are described as (3-aryl-1,2,4-oxadiazol-5-yl)-3,4-dihydro-2H-pyrano[2,3-b]pyridines, with an aryl or heteroaryl group. The patent presents these compounds as potential treatments for fibrotic diseases, particularly renal fibrosis, and other conditions associated with dysregulation of the HIPK2/Smad3 signaling pathway.

Career Highlights

Beresis is associated with the Icahn School of Medicine at Mount Sinai and the United States Department of Veterans Affairs. These affiliations connect his patent activity with biomedical research and the development of potential therapeutic approaches.

Collaborations

His listed coworkers include John Cijiang He and Kyung Lee. Their names appear alongside Beresis’s research and patent-related work.

Conclusion

Richard T. Beresis’s patent work focuses on compounds targeting the HIPK2/Smad3 pathway, with potential applications in treating kidney fibrosis and related fibrotic diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…